Please login to the form below

Not currently logged in
Email:
Password:

Eyevensys

This page shows the latest Eyevensys news and features for those working in and with pharma, biotech and healthcare.

Spark set to file eye disease gene therapy next year

Spark set to file eye disease gene therapy next year

Others include Bristol-Myers Squibb-backed Eyevensys, GenSight Biologics (supported by Novartis), Oxford Biomedica, Avalanche Biotechnologies, Applied Genetic Technologies, and ReGenxbio.

Latest news

  • Boehringer backs gene therapy firm Eyevensys Boehringer backs gene therapy firm Eyevensys

    Boehringer Ingelheim has announced an equity investment in French gene therapy firm Eyevensys, which specialises in the treatment of eye diseases. ... Eyevensys was set up in 2009 and raised 1.6m in its first financing round in early 2012.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics